posted
Schwabie, didn't know that professional A-hole was an actual occupation....IMO if the company has the balls to be asking the shareholders for this type of increase in the A/S then they must be assuming we're going to be a bunch of happy campers by the time October 24th comes around...if w're still at these levels then there is no way the shareholders will approve this increase...I think we're still solid guys...bashers like Schwabie will use this increased A/S vote to scare weak hands out, what other interest would he have in just coming here doing what he does...but remember it's just a vote, it's not happening unless the shareholders let it happen..
IP: Logged |
posted
Our annual stockholders' meeting will be held on October 24, 2006, at 10:00 a.m. eastern daylight savings time, at our corporate headquarters at the New Brunswick Technology Center, 100 Jersey Avenue, Building B, Suite 310, New Brunswick, New Jersey 08901. At our annual meeting, we will ask you to:
o elect three nominees as directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified;
o ratify the selection of Moore Stephens, P.C. as our independent registered public accounting firm for 2006;
o approve the adoption of the 2006 Stock Award Plan authorizing the grant of options to purchase 150,000,000 shares of our common stock;
o approve an amendment to our certificate of incorporation to increase the number of authorized shares of our common stock from 1,950,000,000 to 5,000,000,000, and
o transact any other business that may be properly presented at the annual meeting.
If you were a stockholder of record at the close of business on September 12, 2006, you may vote in person at the annual meeting and any postponements or adjournments of the meeting. A list of these stockholders will be available at our offices before the annual meeting.
Please sign, date and promptly return the enclosed proxy card in the enclosed envelope, so that your shares will be represented whether or not you attend the annual meeting.
By order of the Board of Directors,
Ramesh C. Pandey, Ph.D.
I like this Option better than the 5B o/s increase
o approve the adoption of the 2006 Stock Award Plan authorizing the grant of option to purchase 150,000,000 shares of our common stock
IP: Logged |
posted
Money76 you are a basher, you make all these claims of the stock crashing, and now you predict it is going to go to a dollar. Shady
IP: Logged |
Nigeria: WHO Applauds Nigeria for Sickle Cell Anaemia Drugs
Nigeria First (Abuja)
September 1, 2006 Posted to the web September 1, 2006
Abuja
Nigeria has been applauded for developing two drugs for the treatment of sickle cell anaemia.
She received the stimulating ovation on August 31 in Addis Ababa, Ethiopia when she presented drugs, developed and manufactured by Nigerian indigenous companies, to the 56th session of the World Health Organisation (WHO) Regional Committee Meeting.
The two drugs are Nicosan and Sikilafit.
In his address to the session, Health Minister, Prof. Eyitayo Lambo, credited the drugs to the resolve of Nigeria to look inward for a solution. He said, "sickle cell disease is said to affect between four and five million Nigerians with a great number of people carrying the traits. This makes Nigeria the country with probably the greatest burden."
The recipes for both drugs were obtained from traditional medicine practitioners. The final product is as a result of public-private partnership.
President Olusegun Obasanjo launched the drugs in August.
posted
wow... dollar13 the futures charts at the website are the best I have seen on a free basis.... I may trade some futures shortly if I can find a good commity at an all time low.... Thanks for sharing gr8 job :} I studied Futures trading b4 I learned the stock market..... Lots of risk there and you can loose lots more money than you invest, if the market moves the wrong way.... Thought about Options on the commity market, but there are so many price ranges of the options and if you dont pick the option that ends up having good volume... then you still may not make money.... so FUTURES will b my choice..Thanks Lots
IP: Logged |
posted
************ picked Xkem as one of there picks this month
Home | Recommend | Scoreboard | Previous Picks | Books | Search | Contact Us
************ looks under the rocks to find those little stocks with the potential to make the BIG moves. ************ screens NASDAQ, NYSE, AMEX, and OTC stocks trading under $1. These stocks offer the speculator considerable leverage. It is not uncommon for these stocks to make moves of 30%, 50%, or more. Please read our disclaimer before trading in any stocks mentioned on this Website ... Here's the ************ Report for June 2006:
************ Watch
Here are some stocks we are watching closely!
Our next pick will be 9/4/06!
PTSC
XKEM
DIMEZ
PLNI
AACS
************ picks 3 speculations for Summer 2006....
Patriot Scientific Corp. (OTCBB: PTSC)
Shares of microchip patent-holder Patriot Scientific Corp. soared as much as 50% in trading Friday after the company's joint-venture partner, The TPL Group, announced it had signed a licensing deal with Japanese electronics giant Sony Corp. (NYSE:SNE). The patent portfolio, marketed as the Moore Microprocessor Patent(TM) Portfolio, contains intellectual property that is jointly owned by Patriot Scientific Corp. (OTCBB: PTSC) and the privately held TPL Group. The portfolio encompasses ten U.S. patents as well as European and Japanese counterparts. Both TPL and Patriot assert that their jointly owned patents protect techniques used in designing microprocessors, microcontrollers, Digital Signal Processor (DSPs), embedded processors and System-on-Chip (SoC) implementations. The MMP Portfolio is exclusively managed by Alliacense, a TPL Group enterprise. Global sales of end products deploying chips using technologies protected by the jointly owned patents are estimated to be greater than $200 billion annually.
The validity of the MMP Portfolio has gained substantial momentum since computer chip makers Intel and AMD purchased MMP licenses last year. In addition to Friday's Sony signing, Hewlett-Packard, Casio Computer and Fujitsu have purchased MMP system licenses in 2006. TPL believes that the intellectual property protected by the MMP Portfolio is used in a wide variety of end-user products including personal computers, servers, workstations, home theater systems, digital TVs, video games, DVD Recorders/Players, mobile handsets and automotive electronics.
Shares of PTSC closed at $1.37 on Friday up 35 cents on the day. On Monday, look for shares to break the 52 week high of $2.25 as news of the Sony signing becomes more widely known.
Xechem International, Inc. (OTCBB: XKEM)
Shares of XKEM were up 45% Friday in heavy trading on news that its Nigerian subsidiary, Xechem Pharmaceuticals Nigeria Ltd. (Xechem Nigeria), has successfully closed on a N150 Million Naira ($1.2 million) loan from the Nigerian Export-Import (NEXIM) Bank. Xechem International, Inc. is a development stage biopharmaceutical company whose focus and resources are currently being primarily directed toward the development and commercial launch of NICOSAN (to be marketed as HEMOXIN in the United States and Europe). The drug has shown efficacy in the prophylaxis management of Sickle Cell Disease (SCD).
Dr. Ramesh Pandey, Chairman and CEO of both Xechem International and Xechem Nigeria stated the money received by Xechem Nigeria is to be used primarily to facilitate the expansion of its facility for the commercial scale production of NICOSAN.
Xechem Nigeria has submitted its Drug Master File (DMF) dossier with Nigeria's drug regulatory agency, the National Agency for Food and Drug Administration and Control (NAFDAC), seeking full registration for NICOSAN. It is currently awaiting final word from that agency on its submission. Subject to the necessary approvals, Xechem has indicated that it would like to launch the drug in Nigeria by early July 2006, and shortly thereafter to embark on the clinical trials in the U.S. hospitals for FDA approval through the Investigational New Drug (IND) Application for sale of the drug in the United States.
XKEM closed Friday at 1.6 cents with 84 million shares traded.
************ first looked at DIMEZ back in April 2005 when the Anchor Savings Bank vs United States case was being litigated in Federal Court. It looked like it had 10 bagger plus potential back then and we believe it still does. So what is this all about?
The lawsuit was filed against the United States government way back in January of 1995 by Anchor Bancorp, which later merged with Dime Bancorp. Between 1982 and 1985, Anchor acquired 8 failing savings and loan operations. Four of the acquisitions involved financial assistance from the Federal Savings and Loan Insurance Corporation (FSLIC). Liabilities in these transactions exceeded assets by $650 million. Anchor alleged that FSLIC agreed that this sum could be recorded as goodwill, and that Anchor would not have made the acquisitions if this had not been the case.
Enacted in 1989, the Financial Institutions Reform, Recovery, and Enforcement Act required that the aforementioned goodwill be eliminated immediately. The company argues that this action placed severe restrictions on its activities and forced the company to sell valuable assets under liquidation-like circumstances.
Washington Mutual (NYSE: WM) bought out Dime Bancorp several years ago and inherited Dime Bancorp's lawsuit. The DIMEZ financial instruments are termed warrants, but in fact, are more akin to rights. They offer the buyer an opportunity to receive common stock if a particular event not related to price of the common stock occurs. There is no exercise price, nor is there a definitive expiration date... the warrants expire shortly after litigation has been concluded. The warrants offer purchasers the opportunity to receive 85% of a settlement after taxes and lawyers fees have been taken out. The warrants trade as DIMEZ, although the underlying stock for the warrants is Washington Mutual (NYSE:WM).
The number of shares of Washington Mutual that a holder of the DIMEZ warrants is entitled to after settlement of the litigation is difficult to determine and is dependent on several variables. The trial itself was concluded in July 2005 and we are awaiting the court's decision. The court could award anything from $0 to $983 million. If the judge were to award the maximum amount, it would make the DIMEZ warrants worth somewhere between $7 and $8 …or over 40 times the 17 cents that they closed at on Friday! Far fetched you say? Well, in another S&L breach of contract lawsuit filed against the U.S. government, that of Glendale Federal Bank, Chief Judge Loren A. Smith found that the government was liable for $908.9 million in damages!
Of course, you could also receive nothing. In the event that the court does not award damages, the warrants would be worthless. It is a crap shoot. Don't wager more than you can afford to lose. Shares of DIMEZ were trading around 16 cents at last look.
Well, all right, that's it for now… place your bets, sit back and relax. Remember, this is speculation not investing and quite often we get rewarded BIG for taking a chance…
************.com does not receive compensation from companies we profile or from third parties... we never have and never will. We use our own money when we buy stocks, and even though we usually take a position in a stock before we profile a company, our purchases are small relative to the public float so that the effect on the stock price when we buy or sell is minimal. Please read our full disclaimer.
Also, contrary to a commonly held belief, ************ does not have access to insider information, nor do we want to because trading on insider information is illegal! All information contained in our reports is available in the public record... and any written or verbal communication with company CEOs/IR people strictly adheres to this rule. Readers are urged to read the company SEC filings and do their own due diligence before investing in this or any other stock.
Posted by: keepthfaith In reply to: PokerVertigo who wrote msg# 44045 Date:9/3/2006 2:34:35 PM Post #of 44116
Just stopped in for a moment on this holiday weekend. Fwiw, I spoke at length to Howard Becker on friday. The impression he left was that their alternative to increasing the a/s wouldve been a r/s, which he made clear they are in no way considering. He made the point that they would want the flexibility of possibly using those shares down the road if the company's future was at stake (meaning if for some reason the loans didnt come thru), and that with the loans very likely going thru, most of those newly authorized shares wouldnt be needed except as part of compensation packages for new executive hires. Howard's point was also that this could only be voted on once a year (at the annual meeting) so this was the time when it had to be done. Howard has always been a straight shooter with me, and generally understated (as opposed to my feelings re. Burg). So I do believe what he has to say has merit. Personally, I also have no qualms about the timing of the announcement. If this had to come out, I'm glad it has come PRIOR to any good news out there. I believe the weak hands sold early on friday, and then I think what we began to see friday afternoon was people beginning to realize that there are likely no other shoes to drop, with only positive carrots out there. Just my opinion, but I'm very okay with the response I got to my concerns.
IP: Logged |
posted
Commercial distribution of local sickle cell drug begins
September 4th, 2006
Xechem Pharmaceuticals Nigeria has been given the mandate to market a drug produced locally to combat sickle cell. The drug, Nisprisan, was found and developed by the National Institute for Pharmaceutical Research and Development.
Director-General of NAFDAC, Dora Akunyili made this known in a paper she delivered on ``Sickle Cell Disease: Challenges and Control.'' The paper was presented in Awka on Thursday at this year's African Sickle Cell Day organized by the Orient Sickle Cell Foundation.
``The drug has since been registered by NAFDAC and is now being distributed commercially by Xechem Pharmaceuticals Nigeria as `Nicosan','' she said.
Akunyili said the development was a step in the right direction and urged people suffering from sickle cell not lose hope because theirs was not a hopeless situation.
``I want to remind sickle cell patients that they should disbelieve the impression that they are unlikely to reach adulthood, much less middle or old age.
I encourage you to put in the best of your effort in whatever you do as current researches have proved otherwise. You can live to adulthood with the right medication, '' she said. The director-general said sickle cell was a big challenge to Africans, especially Nigerians who, she said, had the largest population of sickle cell sufferers.
``Sickle cell is not going to go away unless concerted efforts are made by all stakeholders to combat it.
A national programme implemented for this purpose will certainly generate organizational skills and insight, which will be valuable in the execution of other health care initiatives,'' she added. She suggested that the management of sickle cell anaemia should be based at the primary health care level, with emphasis on programmes that could reach more people using affordable technology.
Akunyili assured Nigerians that the agency would always ensure the quality, safety and efficacy of drugs used in the management of sickle cell.
posted
This will be boring from now until things get settled we know now that an r/s in not going to happen
loan shows credability more than no dilution
In crease in a/s shows good business sense if you need money it is there
building of a larger factory and maybe one more. The business plan is now set and the future is more secure that anytime in this company's history i am confident but it is just a waiting game now until investors see the path and plan., A year from now investers will say I can't believe this was a .02 stock. IMHO
IP: Logged |
posted
shakerzz is a guy - part of a group - that buys and sells stocks quickly. They play this stock sometimes and it may cause a price increase then decrease.
I can't believe we have been waiting for the loan news for so long.... I sure hope it comes soon. I hate seeing under 3 cents.
IP: Logged |
posted
Xechem will be presenting and will have a booth at the Sickle Cell Disease Association of America national conference which will be held September 27 - 30, 2006 at the Hyatt Regency Hotel in Dallas. Pandey will reportedly be making a presentation about Nicosan on the Friday the 29th...This has been confirmed through the SCDAA by multiple posters on other boards. Now we all need to push Steve Burg to PR this event. It's free exposure for the company here in the US and needs to be PR'd....we need this while we patiently await the two loans......
IP: Logged |
quote:Originally posted by madmax526: Xechem will be presenting and will have a booth at the Sickle Cell Disease Association of America national conference which will be held September 27 - 30, 2006 at the Hyatt Regency Hotel in Dallas. Pandey will reportedly be making a presentation about Nicosan on the Friday the 29th...This has been confirmed through the SCDAA by multiple posters on other boards. Now we all need to push Steve Burg to PR this event. It's free exposure for the company here in the US and needs to be PR'd....we need this while we patiently await the two loans......
Numerous people called the foundation today and confirmed that Xechem would be there and that Pandey would be speaking...should be some great exposure...if you want the phone number it should be on the website..if not I can find it for you..
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Cool]](cool.gif)
![[Razz]](tongue.gif)
![[Smile]](smile.gif)
